Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial

作者：Thomas Powles, Michiel S. van der Heijden, Y. Loriot, Jens Bedke, Begoña P. Valderrama, Ganesh R. Iyer, Eiji Kikuchi, Jean Hoffman‐Censits, Christof Vulsteke, A. Drakaki, S. Rausch, Waddah Arafat, Se Hoon Park, Umang Swami, J.-R. Li, I. Duran, Seema Rao Gorla, Blanca Homet Moreno, Xin Yu, Yingdong Lu, Shilpa Gupta · 发表于：Annals of Oncology · 年份：2025 · DOI：10.1016/j.annonc.2025.05.536 · 被引用次数：66 · 研究领域：Bladder and Urothelial Cancer Treatments、Cancer Immunotherapy and Biomarkers、Esophageal Cancer Research and Treatment